Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy

References (6)

1. Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection. 2018
2. 10–20. doi:10.1016/j.cmi.2017.12.025 2. Ouédraogo D-D, Tiendrébéogo WJS, Kaboré F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and antirheumatic treatments. Clinical Rheumatology. 2020
3. 2069– 2075 3. Haberman R, Axelrad J, Chen A, Castillo R, Yan D et al. Covid-19 in Immune-Mediated Inflammatory Diseases-Case Series from New York. New England Journal of Medicine. 2020
4. 383(1): 85-88. doi: 10.1056/NEJMc2009567 4. Esatoglu SN, Tascilar K, Babaoğlu H, Bes C, Yurttas B et al. COVID-19 Among Patients With Inflammatory Rheumatic Diseases. Frontiers in Immunology. 2021
5. 651715. doi: 10.3389/fimmu.2021.651715 5. Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D et al. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med (New York). 2020
6. 90– 102. doi: 10.1016/j.medj.2020.11.005